Cargando…
Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models
Anti‐angiogenic therapies have shown limited efficacy in the clinical management of metastatic disease, including lung metastases. Moreover, the mechanisms via which tumours resist anti‐angiogenic therapies are poorly understood. Importantly, rather than utilizing angiogenesis, some metastases may i...
Autores principales: | Bridgeman, Victoria L, Vermeulen, Peter B, Foo, Shane, Bilecz, Agnes, Daley, Frances, Kostaras, Eleftherios, Nathan, Mark R, Wan, Elaine, Frentzas, Sophia, Schweiger, Thomas, Hegedus, Balazs, Hoetzenecker, Konrad, Renyi‐Vamos, Ferenc, Kuczynski, Elizabeth A, Vasudev, Naveen S, Larkin, James, Gore, Martin, Dvorak, Harold F, Paku, Sandor, Kerbel, Robert S, Dome, Balazs, Reynolds, Andrew R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248628/ https://www.ncbi.nlm.nih.gov/pubmed/27859259 http://dx.doi.org/10.1002/path.4845 |
Ejemplares similares
-
Bone-Specific Metastasis Pattern of Advanced-Stage Lung Adenocarcinoma According to the Localization of the Primary Tumor
por: Radeczky, Peter, et al.
Publicado: (2021) -
Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020) -
Role of retinoic receptors in lung carcinogenesis
por: Bogos, Krisztina, et al.
Publicado: (2008) -
The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation
por: Radeczky, Peter, et al.
Publicado: (2021) -
Molecular profiles of small cell lung cancer subtypes: therapeutic implications
por: Schwendenwein, Anna, et al.
Publicado: (2021)